ESC 365 - Pure aortic regurgitation remains off-limits for TAVI - PRO

ESC Premium Access

Pure aortic regurgitation remains off-limits for TAVI - PRO

Session: Controversies in the treatment of aortic valve disease

Topic: Treatment

Speaker: Professor T. Folliguet (Creteil, FR)

Event: ESC Congress 2019

Congress Presentation

About the speaker

Professor Thierry Folliguet

University Hospital Henri Mondor, Creteil (France)

6 presentations

0 follower

5 more presentations in this session

Pure aortic regurgitation remains off-limits for TAVI - CON

Speaker: Doctor R. Makkar (Los Angeles, US)

Pure aortic regurgitation remains off-limits for TAVI - Discussion

Valve-in-valve TAVI regardless of risk profile - PRO

Speaker: Doctor D. Dvir (Jerusalem, IL)

Valve-in-valve TAVI regardless of risk profile - CON

Speaker: Professor G. Gerosa (Padova, IT)

Valve-in-valve TAVI regardless of risk profile - Discussion

Access the full session

Controversies in the treatment of aortic valve disease

Speakers: Professor T. Folliguet, Doctor R. Makkar, Doctor D. Dvir, Professor G. Gerosa

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

Related content

ESC Premium Access

Essential update on Multi-Modality Imaging: best practices to assess mitral regurgitation.

27 August 2021

ESC Premium Access

Multimodality imaging for diagnosis of a left ventricular free-wall rupture after acute myocardial infarction: Too small to be seen?

27 August 2021

ESC Premium Access

Acute aortic syndrome in young population. A contemporary approach.

27 August 2021

ESC 365 is supported by